7 signals · News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Moderate risk indicators present across data sources.
Auto-generated from public signals — AI summary pending. Based on 3 recent signals.
Recursion Pharmaceuticals (RXRX) Stock Faces Q3 Results Cash Burn Question Simply Wall St
Recursion Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.32, Implies 76% Upside TradingView
Stock 12‑Month Price Target Raised to $7.32, Implies 76% Upside TradingView
AI-driven drug discovery platform.
Based on 7 signals across 1 source · snapshot 4 Nov 2026
Limited: treat this score as early-stage, more data needed.
Overall community sentiment for Recursion Pharmaceuticals is negative based on public signals as of 4 Nov 2026.
Limited coverage — score may shift as signals arrive.
Based on 7 signals across 1 source
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
Recursion Pharmaceuticals Q2 2026 Results: OPEX guidance cut 40% to $375 million scanx.trade